Discontinued — last reported Q4 '17

Non-Current Assets

Indefinite-Lived Research and Development Assets

Abbott Indefinite-Lived Research and Development Assets increased by 16.7% to $902.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 16.7%, from $773.00M to $902.00M. This is a positive signal — higher values indicate stronger performance for this metric.

Analysis

StatementBalance Sheet Statement
SectionNon-Current Assets
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ3 2015
Last reportedQ4 2017

How to read this metric

An increase indicates active investment in future technology, while a decrease may signal project completion or impairment.

Detailed definition

These are acquired in-process research and development (IPR&D) projects that have not yet reached technological feasibil...

Peer comparison

Common in technology and pharmaceutical sectors following M&A activity.

Metric ID: indefinite_lived_rd_assets

Historical Data

5 periods
 Q4 '21Q4 '22Q4 '23Q4 '24Q4 '25
Value$0.00$319.00M$568.00M$773.00M$902.00M
QoQ Change+78.1%+36.1%+16.7%
YoY Change+78.1%+36.1%+16.7%
Range$0.00$902.00M
Avg YoY Growth+43.6%
Median YoY Growth+36.1%
Current Streak3+ quarters growth

Indefinite-Lived Research and Development Assets at Other Companies

Frequently Asked Questions

What is Abbott's indefinite-lived research and development assets?
Abbott (ABT) reported indefinite-lived research and development assets of $902.00M in Q4 2025.
How has Abbott's indefinite-lived research and development assets changed year-over-year?
Abbott's indefinite-lived research and development assets increased by 16.7% year-over-year, from $773.00M to $902.00M.
What does indefinite-lived research and development assets mean?
The value of research projects acquired from other companies that are still in progress.